Very Low-Dose Intratympanic Gentamicin in Ménière’s Disease

Background: Intratympanic gentamicin is widely used for vertigo control in patients with Ménière’s disease refractory to conservative therapy. Dose titration aims to achieve vestibular ablation while preserving cochlear function. Aim: To evaluate the efficacy and safety of a very low-dose intratympanic gentamicin protocol in patients with endolymphatic hydrops and disabling vertigo. Methods: This prospective clinical case series included 27 patients with definite Ménière’s disease who failed medical treatment. Gentamicin sulfate (5 mg/mL) was administered every 12 hours through a tympanostomy tube. Treatment was discontinued at the first subjective sign of ototoxicity. Mean duration of treatment approximately 9 days. Follow-up ranged from 6 months to 4 years. Primary outcome was vertigo control. Secondary outcomes included hearing level, tinnitus, and vestibular function. Results: Vertigo control was achieved in 96% (26/27) of patients. Hearing was preserved or improved in 92% (25/27). Tinnitus was unchanged or improved in 23 patients and worsened in four. Vestibular function was unchanged in four patients, reduced in 17, and absent in six. Conclusions: Very low-dose intratympanic gentamicin provides good vertigo control with a high rate of hearing preservation. It represents a simple, and cost-effective alternative to destructive surgical procedures in selected patients with refractory Ménière’s disease. Received: 23 June 2026 │ Accepted: 29 October 2026 │ Published: 20 November 2026

Authors

Institutions

Publication Details

Journal
Interdisciplinary Journal of Research and Development
Published
2026-11-20
DOI
https://doi.org/10.56345/ijrdv13n313
Primary Topic
Vestibular and auditory disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Very Low-Dose Intratympanic Gentamicin in Ménière’s Disease

Trifon Kiratzidis, Evis Bendo
Interdisciplinary Journal of Research and Development
Vestibular and auditory disorders
article

Very Low-Dose Intratympanic Gentamicin in Ménière’s Disease

Trifon Kiratzidis, Evis Bendo
article en

Abstract

Background: Intratympanic gentamicin is widely used for vertigo control in patients with Ménière’s disease refractory to conservative therapy. Dose titration aims to achieve vestibular ablation while preserving cochlear function. Aim: To evaluate the efficacy and safety of a very low-dose intratympanic gentamicin protocol in patients with endolymphatic hydrops and disabling vertigo. Methods: This prospective clinical case series included 27 patients with definite Ménière’s disease who failed medical treatment. Gentamicin sulfate (5 mg/mL) was administered every 12 hours through a tympanostomy tube. Treatment was discontinued at the first subjective sign of ototoxicity. Mean duration of treatment approximately 9 days. Follow-up ranged from 6 months to 4 years. Primary outcome was vertigo control. Secondary outcomes included hearing level, tinnitus, and vestibular function. Results: Vertigo control was achieved in 96% (26/27) of patients. Hearing was preserved or improved in 92% (25/27). Tinnitus was unchanged or improved in 23 patients and worsened in four. Vestibular function was unchanged in four patients, reduced in 17, and absent in six. Conclusions: Very low-dose intratympanic gentamicin provides good vertigo control with a high rate of hearing preservation. It represents a simple, and cost-effective alternative to destructive surgical procedures in selected patients with refractory Ménière’s disease. Received: 23 June 2026 │ Accepted: 29 October 2026 │ Published: 20 November 2026

Interdisciplinary Journal of Research and DevelopmentVol. 13(3)
Mother Teresa Hospital (AL), Veria General Hospital (GR)
Good health and well-being
Vestibular and auditory disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Very Low-Dose Intratympanic Gentamicin in Ménière’s Disease — Trifon Kiratzidis, Evis Bendo · Interdisciplinary Journal of Research and Development (2026) | TGRS Research Map | TGRS